drugset / Trial / NCT02941016

Vascular Inflammation and Cholesterol Lowering Therapy

NCT02941016

Phase 4 Withdrawn Rigshospitalet, Denmark
NaSingle-groupOpen-labelOther

Summary

This study aim to detect change in vascular inflammation following intense lipid lowering therapy

Timeline

Start
2016-10
Primary completion
2020-10
Completion
2020-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Alirocumab Monoclonal antibody
Subject Evolocumab Monoclonal antibody